Journal
ONCOIMMUNOLOGY
Volume 1, Issue 7, Pages 1175-1177Publisher
LANDES BIOSCIENCE
DOI: 10.4161/onci.20594
Keywords
bladder cancer; metastasis; RhoGDI2; versican; inflammation
Categories
Funding
- NCI NIH HHS [R01 CA143971] Funding Source: Medline
Ask authors/readers for more resources
Low expression of RhoGDI2 is associated with poor outcome in cancer patients. In animal models, RhoGDI2 suppresses lung metastasis by reducing the expression of the proteoglycan versican, whose levels portend poor patient prognosis. Versican promotes metastasis through enhanced tumor migration and creation of an inflammatory lung environment involving macrophages and the CCL2/CCR2 signaling axis. Targeting this mechanism may provide novel adjuvant strategies for delaying the appearance of clinical metastasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available